• A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

  NCT06900920

  RecruitingInterventionalPhase 3Updated May 20, 2025
• Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

  NCT07455006

  Not yet recruitingInterventionalPhase 3Updated Mar 6, 2026
• Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

  NCT05621330

  CompletedInterventionalPhase 3Updated Nov 23, 2022
• A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

  NCT04412577

  Unknown statusInterventionalPhase 1Updated Apr 1, 2021
• A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

  NCT06211751

  Unknown statusInterventionalPhase 1Updated Jan 18, 2024
• A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

  NCT06566586

  RecruitingInterventionalPhase 2Updated Nov 20, 2024

ClinicalTrials.gov ID

NCT07083739

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

320Estimated

Last Update Posted

Jul 24, 2025Actual

Start Date

Aug 2025Estimated

Primary Completion Date

Sep 2027Estimated

Completion Date

Mar 2028Estimated

Official Title

Phase II Clinical Trial on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Brief Summary

This study is an extension of the TQB3473-III-01 study, aimed at evaluating the safety and efficacy of TQB3473 tablets in adult patients with persistent or chronic ITP who have received at least one ITP standard treatment that is ineffective or has recurred after treatment. This is a single arm, open label, multi cohort, multi center Phase II clinical study.

• Primary Immune Thrombocytopenia

• TQB3473 Tablets

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Cohort 1 :

• Voluntarily participate in this study with signed informed consent form (ICF) and demonstrated good compliance.
• Age ≥18 years (calculated from the date of ICF signing); no gender restrictions; Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Clinically stable condition with WHO bleeding scale score 0-1, and investigator assessment indicates no need for emergency treatment within the next 2 weeks.
• No increase in the type, dosage, or frequency of concomitant ITP medications compared to the TQB3473-III-01 study regimen.
• Previous participation in the TQB3473-III-01 study with either: Sustained platelet count <30×10⁹/L during the 12-week pre-randomization period (<50×10⁹/L if emergency treatment was received), or completion of 24-week double-blind treatment with investigator-confirmed benefit-risk assessment favoring continued therapy.
• Adequate major organ function as defined by protocol criteria.
• For women of childbearing potential: Must agree to use highly effective contraception from screening through 6 months after treatment completion and refrain from oocyte donation for reproductive purposes during this period; must not be breastfeeding with negative serum/urine pregnancy test within 7 days prior to enrollment. For male participants with fertile partners: Must agree to use effective contraception during the study and for 6 months thereafter.

Cohort 2 ：

• Subjects voluntarily participate in this study upon signing the Informed Consent Form (ICF) with demonstrated compliance.
• Age ≥ 18 years (calculated from signing date of ICF); No gender restrictions; ECOG performance status score 0-1.
• Confirmed diagnosis of primary ITP >3 months prior to enrollment.
• Clinically stable condition with WHO bleeding score 0-1, no major bleeding episodes within 4 weeks pre-randomization, and investigators confirm no anticipated need for emergency treatment within 2 weeks.
• Meeting all platelet criteria: Mean platelet count <30×10⁹/L (no single value >35×10⁹/L) from ≥2 independent measurements (≥3 days apart) within 7 days pre-enrollment Confirmed platelet count <30×10⁹/L within 24 hours before enrollment.
• Documented failure or relapse after ≥1 prior standard ITP therapy.
• Adequate function of major organs per protocol definitions.
• Permitted ≤1 concurrent ITP treatment (any class), provided: Stable dose maintained for ≥4 weeks prior to enrollment (≥2 weeks for corticosteroids)
• For women of childbearing potential: Must agree to use highly effective contraception from screening through 6 months after treatment completion and refrain from oocyte donation for reproductive purposes during this period; must not be breastfeeding with negative serum/urine pregnancy test within 7 days prior to enrollment. For male participants with fertile partners: Must agree to use effective contraception during the study and for 6 months thereafter.

Exclusion Criteria:

• Cohort 1 :

  1. Due to reasons other than lack of efficacy, receiving TQB3473-III-01 study treatment for less than 12 weeks.
  2. Hepatitis B Virus (HBV) DNA or Hepatitis C Virus (HCV) RNA detection values exceeding the upper limit of normal or decompensated cirrhosis
  3. Previous intracranial hemorrhage or severe bleeding of other important organs (≥ CTC AE grade 3), or symptomatic gastrointestinal bleeding (such as vomiting blood, black stool, etc., except for asymptomatic and asymptomatic "occult blood test positive" and hemorrhoids) within the 6 months before enrollment.
  4. Suffering from major cardiovascular and cerebrovascular diseases.
  5. There are multiple factors that can affect oral medication, such as inability to swallow, chronic diarrhea, and intestinal obstruction.
  6. Those who have received major surgical treatment, significant traumatic injury, or are expected to undergo major elective surgery during the study treatment period within the 4 weeks prior to enrollment
  7. Uncontrolled significant active infections (such as sepsis, pneumonia, or abscess), or severe infections within the 12 weeks prior to enrollment (resulting in hospitalization or requiring antibiotic treatment).
  8. Vaccination was administered within 8 weeks prior to enrollment, or planned during the study period.
  9. Received blood transfusions or blood products within 2 weeks prior to enrollment (excluding IVIg used for emergency treatment).
  10. Take strong CYP3A inhibitors or inducers (3 weeks for Forsythia suspensa) for 2 weeks or 5 half lives (whichever is longer) before enrollment.
  11. Long term/continuous treatment with drugs that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulant therapy is required.
  12. Allergic constitution or history of severe allergies, or known allergies to the components of the investigational drug excipients.
  13. There are clear neurological or mental disorders, or serious psychological or mental abnormalities.
  14. Alcoholic or drug abusers.
  15. According to the researcher's perspective, other severe, acute, or chronic medical or mental illnesses or laboratory abnormalities that may increase the risks associated with participating in the study or interfere with the interpretation of the research results.
  16. It is estimated that the patient's compliance in participating in this clinical study is insufficient.

Cohort 2：

• There is evidence to suggest the presence of secondary causes of ITP in the subjects, or immune cell depletion of two or more lineages, such as Evans syndrome;

• Past or current presence of myelofibrosis, myelodysplastic syndrome, aplastic anemia, lymphoproliferative disorders, or other malignant hematological diseases.

• Have had or currently have malignant tumors within the past 3 years. The following two situations can be included in the group: other malignant tumors treated with a single surgery, achieving continuous 5-year disease-free survival (DFS); Cured cervical carcinoma in situ, non melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basement membrane)].

• HBV DNA or HCV RNA detection values exceeding the upper limit of normal or decompensated cirrhosis.

• Previous intracranial hemorrhage or severe (≥ Common Terminology Criteria (CTC) AE grade 3) bleeding of other important organs, or symptomatic gastrointestinal bleeding (such as vomiting blood, black stool, etc., except for asymptomatic and asymptomatic "occult blood test positive" and hemorrhoids) within the 6 months before enrollment.

• Suffering from major cardiovascular and cerebrovascular diseases.

• There are multiple factors that can affect oral medication, such as inability to swallow, active gastric ulcers, major gastrointestinal surgeries, chronic diarrhea, and intestinal obstruction.

• ITP related symptoms and treatment:

  • Received ITP emergency treatment within 2 weeks prior to enrollment;
  • Received platelet transfusion within 2 weeks prior to enrollment;
  • Received immunoglobulin or traditional Chinese medicine treatment within 2 weeks before enrollment;
  • Used rituximab or other anti-Cluster of Differentiation 20 (CD20) drugs within 14 weeks prior to enrollment;
  • Received splenectomy within 12 weeks prior to enrollment;
  • Individuals who have received glucocorticoids within the 2 weeks prior to enrollment, or have received thrombopoietin drugs (rhTPO, eltrombopag, hetrombopag, avatrombopag, romiplostim), immunomodulators (azathioprine, cyclosporine A, mycophenolate mofetil), chemotherapy drugs (decitabine, vinblastine), danazol, etc. within the 4 weeks prior to enrollment, except for those who meet the inclusion criteria 8 and are allowed to undergo concomitant treatment.

• Adverse reactions from previous treatments that have not recovered to ≤ CTCAE grade 1, as well as non clinically significant and asymptomatic laboratory abnormalities that have been determined by researchers to pose no safety risks, are excluded.

• Patients who have received major surgical treatment, significant traumatic injury, or are expected to undergo major elective surgery during the study treatment period within the 4 weeks prior to enrollment (major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition).

• Vaccination was administered within 8 weeks prior to enrollment, or planned during the study period.

• Uncontrolled significant active infections (such as sepsis, pneumonia, or abscess), or severe infections within the 12 weeks prior to enrollment (resulting in hospitalization or requiring antibiotic treatment).

• Received blood transfusions or blood products within 2 weeks prior to enrollment (excluding intravenous immunoglobulin (IVIg) used for emergency treatment).

• Take strong Cytochrome P450 3A (CYP3A) inhibitors or inducers (3 weeks for Forsythia suspensa) for 2 weeks or 5 half lives (whichever is longer) before enrollment.

• Participants who have participated in and used other clinical trial drugs within 4 weeks prior to enrollment.

• Long term/continuous treatment with drugs that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulant therapy is required.

• Allergic constitution or history of severe allergies, or known allergies to the components of the investigational drug excipients.

• History of important organ transplantation or hematopoietic stem cell/bone marrow transplantation.

• History of immunodeficiency, including HIV positivity or other congenital immunodeficiency diseases.

• Individuals with epilepsy who require treatment.

• There are clear neurological or mental disorders, or serious psychological or mental abnormalities.

• Alcoholic or drug abusers.

• According to the researcher's perspective, other severe, acute, or chronic medical or mental illnesses or laboratory abnormalities that may increase the risks associated with participating in the study or interfere with the interpretation of the research results.

• It is estimated that the patient's compliance in participating in this clinical study is insufficient.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

13837203600@139.com13837203600

18336637929@163.com18336637929

papertigerhu@163.com13939068863

rfzhoucn@163.com13605142342

heguangsheng1972@sina.com15312052798

jxdxz1989@163.com13576686139

Gaoguangxun@fmmu.edu.cn13991907320

Cxq@nwu.edu.cn13991832567

guitaojie@126.com13869997389

hsl393@163.com19935261898